Navigation Links
Prana Biotechnology Presents New Key Findings on PBT2

ker protein synaptophysin.

The amyloid plaques which are the main pathological feature of the brains of Alzheimer's sufferers are composed of aggregates of the Abeta protein. The Alzheimer's research community largely supports the hypothesis that small, soluble, mobile aggregates (oligomers) of the Abeta protein are the cause of neurotoxicity in AD. PBT2's ability to inhibit the generation and toxicity of these oligomers, as well as preventing the hyperphosphorylation of tau, while improving cognition, supports the disease modifying potential of PBT2 and other drugs in the Prana development pipeline.

Geoffrey Kempler, Chairman and Chief Executive Officer of Prana commented: "The results of these studies are encouraging and lend further support to the theories driving development of PBT2. We continue to improve our understanding of PBT2's functionality and potential for disease modification as we move forward with formal clinical development. The ongoing PBT2 Phase IIa trial in early Alzheimer's patients is on track to complete dosing by the end of this year and report early in 2008."

The technique of in vivo brain microdialysis recently adopted as a research tool by Prana scientists provides a unique insight into a dynamic metabolic process, allowing researchers to sample secretions from the brains of conscious, unrestrained test animals freely interacting with their environment. Sampling from the brains of genetically-engineered AD mouse models which have received single or sequential oral doses of PBT2, it was found that the drug exerts its inhibitory effects upon the target molecule, Abeta, rapidly and reproducibly without causing "rebound" effects observed with other drugs in development. Most particularly, a dramatic reduction was observed in soluble oligomers of the size range identified in the literature as the most toxic form of Abeta amyloid in AD.

The findings of these studies confirm and expand upon data presented by the Compan
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
2. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
3. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
4. Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease
5. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ASCO Annual Meeting
6. Generex Biotechnology Vaccine Strategy Presented at International Conference in London
7. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at AUA Annual Meeting
8. Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR Annual Meeting Late-Breaking Clinical Trials Session
9. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
10. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
11. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Prana Biotechnology Presents New Key Findings PBT2
(Date:12/15/2009)... -- Cumberland Pharmaceuticals Inc. ( CPIX) ... results for a patient preference study evaluating Kristalose ... laxative packaged as a crystalline powder, compared to ... the only prescription-strength laxative available in pre-measured powder ... a recent diagnosis of chronic constipation were administered ...
(Date:12/15/2009)... healthcare providers who have already immunized patients most ... virus may now offer the vaccine to anyone ... today. ,, Pennsylvania is expanding the H1N1 ... doses of vaccine have been allocated to healthcare ... priority groups. ,, "Many certified providers have already ...
(Date:12/15/2009)... LAKE ZURICH, Ill., Dec. 15 Fenwal ... improving blood collection, separation, safety and availability, announced ... has granted Fenwal approval to market InterSol ® ... InterSol ® solution is a specialized product ... donated platelets, a vital blood component used to ...
Breaking Medicine Technology:Kristalose(R) Preferred by Patients With Chronic Constipation Compared to Similar Products in a Recent Study 2Kristalose(R) Preferred by Patients With Chronic Constipation Compared to Similar Products in a Recent Study 3Department of Health Urges Expanded H1N1 Vaccination Efforts to Include All Patients 2Fenwal Receives FDA Approval for New Solution Used to Store Donated Blood Platelets 2New Online Tutorials for IMG IMG M NCBI Viral Genomes and VBRC 60043 1New Online Tutorials for IMG IMG M NCBI Viral Genomes and VBRC 60043 2New Online Tutorials for IMG IMG M NCBI Viral Genomes and VBRC 60043 3New Online Tutorials for IMG IMG M NCBI Viral Genomes and VBRC 60043 4Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Gly 60041 1Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Gly 60041 2Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Gly 60041 3Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Gly 60041 4Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Gly 60041 5Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Gly 60041 6Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Gly 60041 7Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Gly 60041 8Study shows how carbon nanotubes can affect lining of the lungs 10514 1Study shows how carbon nanotubes can affect lining of the lungs 10514 2
... total funding expected by year,s end, NEW ... pluripotent stem cell technology are among the cutting-edge,approaches ... J.,Fox Foundation,s Rapid Response Innovation Awards 2008. As ... a cure for PD, the,Foundation has awarded $1.1 ...
... Echo Therapeutics,(OTC Bulletin Board: ECTE) today announced ... Symphony(TM) Transdermal Continuous Glucose Monitoring (tCGM),System in ... Diabetes. Echo,s non-invasive,Symphony tCGM System consists of ... the Prelude(TM) SkinPrep System, which,incorporates leading-edge, needle-free ...
Other Medicine Technology:Michael J. Fox Foundation Funds $1.1 Million for Cutting-Edge Approaches to Parkinson's Disease Under Rapid Response Innovation Awards 2008 2Michael J. Fox Foundation Funds $1.1 Million for Cutting-Edge Approaches to Parkinson's Disease Under Rapid Response Innovation Awards 2008 3Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes 2Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes 3Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes 4
(Date:12/15/2009)... Calif., Dec. 15 Senetek PLC (OTC Bulletin Board: SNKTY), a Life Sciences company ... aging, today announced that shareholders had approved all three resolutions that the Company had proposed ... as follows: , , Description of ... Votes ... For ...
(Date:12/15/2009)... will be donated to the Lupus Foundation of America ... WASHINGTON, Dec. 15 Julian Lennon, son of ... released their new digital single, "LUCY," to raise funds ... March 15, 2010, 100 percent of the proceeds from ... Lupus Foundation of America (LFA), and the Saint Thomas, ...
(Date:12/15/2009)... lower dementia risk, research finds , , TUESDAY, Dec. 15 ... hormone that regulates appetite, may guard against Alzheimer,s disease, ... years this may be one of many agents that ... said senior study author Dr. Sudha Seshadri, an associate ... "Or it may be one of many markers that ...
(Date:12/15/2009)... delivered ,, WASHINGTON, Dec. 15 ... that healthcare reform does not override the prostate ... in 37 states. ,, Prostate cancer screening is ... and individuals who are identifiable as high risk, ... a family history of prostate cancer. The American ...
(Date:12/15/2009)... 15 Team In Training (TNT), The ... charity sports training program, has reached a remarkable ... cancer research and patient services. ,, For more ... charity endurance sports training program, preparing amateurs and ... triathlon, 100-mile century cycle ride or hike adventure. ...
Breaking Medicine News(10 mins):Health News:Senetek PLC Announces 2009 Annual General Meeting Voting Results 2Health News:Senetek PLC Announces 2009 Annual General Meeting Voting Results 3Health News:Julian Lennon and James Scott Cook Release New Charity Single 'LUCY' to Raise Awareness and Funds for Lupus Research 2Health News:Fat Hormone May Protect Against Alzheimer's 2Health News:Fat Hormone May Protect Against Alzheimer's 3Health News:Men's Health Network Calls on Congress to Complete President Obama's Promise on Health Care Reform 2Health News:$1 Billion - For Charity! 2Health News:$1 Billion - For Charity! 3
... may be the answer in developing ... ... Cancer,Prevention (ACCP), a partnership of five international public health,research organizations, today announced ... 20 countries in Africa,Asia, and Latin America. At the top of the ...
... March 5 The Pharmaceutical,Research and Manufacturers of ... in the research pipeline for neurological diseases. The ... new,medicines to help treat neurological diseases., "We ... its particular,relevance to the health of this city,s ...
... the one in three adults who fail to take their ... everyone else who occasionally forgets: a sensor necklace that records ... and reminds the user if any doses are being missed. ... but so is taking the medication at the wrong time, ...
... perspective on empowered consumers at,Best Practices Conference and ... Most of the discussion,surrounding health care reform ... wield enormous potential power for changing an,onerous health ... Empowering consumers to become "smart patients" will ...
... anchor ... depth, ANDOVER, ... Endoscopy Division today announced the launch of the,BIORAPTOR 2.3 PK Suture Anchor ... featured at Smith & Nephew Endoscopy,s booth,at the American Academy of Orthopedic ...
... 5 The Chartis Group, a leading,healthcare advisory ... Pamela Damsky, James Karpook and Gregory Maddrey to ... leading healthcare,organizations in advancing their strategic, organizational and ... tremendous asset to our clients and our,firm. Greg, ...
Other Medicine News:Health News:New Findings Support Alternatives to Pap Test 2Health News:New Findings Support Alternatives to Pap Test 3Health News:New Findings Support Alternatives to Pap Test 4Health News:Report on 547 New Medicines in Development for Neurological Disorders Released in San Antonio 2Health News:Report on 547 New Medicines in Development for Neurological Disorders Released in San Antonio 3Health News:Sensor necklace aims to increase elderly and clinical trial participant drug compliance 2Health News:Sensor necklace aims to increase elderly and clinical trial participant drug compliance 3Health News:Sensor necklace aims to increase elderly and clinical trial participant drug compliance 4Health News:Cultivating the Smart Patient: Author and RealAge Founder Michael F. Roizen, MD to Present Keynote at URAC Conference 2Health News:Cultivating the Smart Patient: Author and RealAge Founder Michael F. Roizen, MD to Present Keynote at URAC Conference 3Health News:Smith & Nephew Endoscopy's BIORAPTOR(TM) 2.3 PK Suture Anchor Provides Secure Repair for Shoulder, Hip Instability 2Health News:Smith & Nephew Endoscopy's BIORAPTOR(TM) 2.3 PK Suture Anchor Provides Secure Repair for Shoulder, Hip Instability 3Health News:Smith & Nephew Endoscopy's BIORAPTOR(TM) 2.3 PK Suture Anchor Provides Secure Repair for Shoulder, Hip Instability 4Health News:The Chartis Group Elects New Partners: Four Healthcare Industry Experts Promoted to Principal 2Health News:The Chartis Group Elects New Partners: Four Healthcare Industry Experts Promoted to Principal 3
... autoLog™ Autotransfusion System processes blood collected ... washed red blood cells for return ... time. This is achieved with only ... innovative bowl design, coupled with sophisticated ...
The hipGRIP® is a twenty piece modular lateral positioning system which provides positive pelvis control with an innovative positioning system....
The Simpulse®VariCare™ System provides an innovative system for enhanced wound management which emphasizes performance, simplicity, safety, value, and support....
... staples are especially useful in ... including anterior cruciate reconstruction. They ... fixation, tendon and ligament repair ... Four sizes are available, in ...
Medicine Products: